Aurinia Pharmaceuticals (AUPH) 13.33M Share Common Offering at $15/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Aurinia Pharmaceuticals (AUPH) Announces Public Offering of Common Share
July 22, 2020 4:08 PM EDTAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (TSX: AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has commenced a registered underwritten public offering of its common shares (the Offering).
Jefferies... More
Aurinia Pharmaceuticals (AUPH) Pushes to Session Highs Following FDA Acceptance of Voclosporin NDA; Shares Up 14%
July 22, 2020 11:57 AM EDTAurinia Pharmaceuticals (NASDAQ: AUPH) pushes to session highs after the FDA accepted the filing of its NDA for voclosporin, as a potential treatment for lupus nephritis (LN). H.C. Wainwright raised the price target on Aurinia to $33. Shares are up 14.4%.
... MoreAurinia Pharmaceuticals (AUPH) PT Raised to $33 at H.C. Wainwright
July 22, 2020 11:14 AM EDTH.C. Wainwright analyst Ed Arce raised the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $33.00 (from $32.00) while maintaining a Buy rating announced that the FDA has accepted the filing of its NDA for voclosporin for the treatment of lupus nephritis (LN), a serious inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus (SLE).
The analyst commented, "As... More
Aurinia Pharmaceuticals (AUPH) Announces FDA Acceptance of Filing of NDA and Priority Review for Voclosporin for Treatment of Lupus Nephritis
July 21, 2020 5:28 PM EDTAurinia Pharmaceuticals Inc. (Nasdaq: AUPH), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for voclosporin, as a potential treatment for lupus nephritis (LN), a serious inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus (SLE). The FDA has granted Priority Review for the... More
